Double-Blind, Four Week Trial Of [S,S]-Reboxetine And Atomoxetine In Adults With Attention Deficit Hyperactivity Disorder.

Phase 2, Randomized, Double-Blind, Parallel-Group, Four Week, Efficacy And Safety Trial Of [S,S]-Reboxetine (PNU-165442g) And Atomoxetine In Adults With Attention Deficit Hyperactivity Disorder.

Status

Withdrawn

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00562055

Enrollment

Registered

2007-11-21

Start date

2007-11-30

Completion date

Unknown

Last updated

2019-04-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Attention Deficit Hyperactivity Disorder

Brief summary

This study will compare the safety and efficacy of \[S,S\]-reboxetine to atomoxetine in the treatment of adult patients with attention deficity-hyperactivity disorder.

Interventions

DRUGAtomoxetine

DRUGPNU-165442G; [S,S]-reboxetine

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE

Eligibility

Sex/Gender

ALL

Age

18 Years to 55 Years

Healthy volunteers

Inclusion criteria

1. Diagnosis of Attention Deficit Hyperactivity Disorder according to DSM-IV criteria. 2. Score of 24 or higher on the Adult ADHD Investigator Symptom Rating Scale 3. Score of 4 or higher on the Clinician Global Impression - Severity scale

Exclusion criteria

1. Significant comorbid psychiatric diagnoses 2. Significant risk of suicidal or violent behavior

Design outcomes

Primary

Measure	Time frame
Adult ADHD Investigator Symptom Rating Scale - Total Score	4 weeks

Secondary

Measure	Time frame
Adult ADHD Investigator Symptom Rating Scale - Inattention Subscale Score	4 weeks
Adult ADHD Investigator Symptom Rating Scale - Hyperactivity/Impulsivity Subscale Score	4 weeks

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026